Jason M. Broderick

The reduction of breast cancer risk with 5 years of tamoxifen does not outweigh the lack of a mortality benefit, according to J. Michael Dixon, MD, OBE, who shared his view in a session at the 32nd Annual Miami Breast Cancer Conference.

Carfilzomib doubled progression-free survival versus bortezomib in patients with relapsed multiple myeloma in the phase III ENDEAVOR trial.

In a discussion at the Miami Breast Cancer Conference, Clifford A. Hudis, MD, suggested that an increased risk for developing breast cancer might be a consequence of inflammation that often accompanies obesity.

The FDA has granted a priority review to nivolumab for use in patients with previously treated, advanced, squamous non–small cell lung cancer.

Tumor genome profiling identifies driver mutations in breast tumors, however, it is still too early to use this information in clinical decision making.

The FDA has accepted an NDA for the oral nucleoside TAS-102 as a treatment for patients with refractory metastatic colorectal cancer.

The spliced androgen receptor variant AR-V7 was not shown to be a biomarker for chemotherapy efficacy in advanced prostate cancer, according to a small prospective study presented in a presscast held ahead of the 2015 Genitourinary Cancers Symposium.

Jeffrey Jones, MD, presented evidence supporting the integration of obinutuzumab, ibrutinib, ofatumumab, and idelalisib into the frontline setting for patients with chronic lymphocytic leukemia.

The FDA has granted a priority review to the MEK inhibitor cobimetinib for use in combination with the BRAF inhibitor vemurafenib (Zelboraf) to treat patients with BRAF V600–positive advanced melanoma.

Ibrutinib (Imbruvica) showed promising activity in heavily pretreated, relapsed/refractory chronic lymphocytic leukemia after allogeneic stem cell transplantation, according to data presented at the American Society for Blood and Marrow Transplantation 2015 BMT Tandem Meeting.

The FDA has approved lenalidomide (Revlimid) plus dexamethasone in newly diagnosed patients with multiple myeloma based on findings from the phase III FIRST trial.

The oral multikinase inhibitor motesanib failed to meet the primary endpoint of improving progression-free survival in patients with non–small cell lung cancer in the phase III MONET-A trial.

The FDA has granted approval to lenvatinib (Lenvima) as a treatment for patients with progressive, radioactive iodine-refractory differentiated thyroid cancer.

With a deadline of April 14, the FDA will soon make its final approval decision on the oral multikinase inhibitor lenvatinib as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).

A phase III study of obinutuzumab in indolent non-Hodgkin lymphoma has been stopped early after a positive interim analysis.

The FDA has granted a priority review to trabectedin (Yondelis) to treat patients with advanced soft tissue sarcoma.

The anti–PD-L1 agent MPDL3280A has received a breakthrough therapy designation from the FDA for PD-L1–positive non–small cell lung cancer that has progressed during or after platinum-based chemotherapy, as well as a targeted therapy for patients with EGFR- or ALK-positive tumors.

For additional insight on the published RESPONSE data and the use of ruxolitnib to treat polycythemia vera, we reached out to Richard Levy, MD, executive vice president and chief drug development and medical officer at Incyte, the company that co-manufactures ruxolitinib with Novartis.

The FDA has granted a Fast Track Designation to CPX-351, a liposomal formulation of cytarabine and daunorubicin, for the treatment of elderly patients with relapsed acute myeloid leukemia (AML).

Daniel Hayes, MD, was recently elected president of ASCO. OncLive sat down with him for a Q&A.

Second-line treatment with the VEGFR2 inhibitor ramucirumab (Cyramza) combined with standard FOLFIRI extended survival by 1.6 months versus FOLFIRI alone in patients with metastatic colorectal cancer (mCRC), according to results from the phase III RAISE trial.

Nivolumab improved survival versus docetaxel in patients with pretreated squamous cell non–small cell lung cancer in the phase III CheckMate-017 trial.

For some insight on this discussion, OncLive sat down with prostate cancer expert and president-elect of SUO, Leonard G. Gomella, MD.

In a 14-0 vote, the FDA's ODAC unanimously recommended approval of EP2006, a biosimilar version of filgrastim. If the FDA follows the recommendation, the drug would become the first biosimilar approved in the United States.

Frontline treatment with everolimus (Afinitor) combined with trastuzumab (Herceptin) and paclitaxel failed to delay disease progression versus trastuzumab and paclitaxel alone in patients with HER2-positive advanced breast cancer

Women with HR+ breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant exemestane or-to a lesser extent-tamoxifen, compared with standard tamoxifen alone, according to results from the phase III SOFT trial.

Among HER2-positive breast cancer patients treated with chemotherapy alone, women with high levels of stromal tumor-infiltrating lymphocytes had an 80% lower likelihood of disease recurrence compared to those with lower TIL counts.

Both HPV-positive and -negative head and neck cancers are "outstanding candidates for immunotherapeutic strategies," said Andrew G. Sikora, MD, PhD, Baylor College of Medicine, at the 2014 Chemotherapy Foundation Symposium.

The landscape in lymphoma management continues to evolve, with new therapies and approaches improving established treatment paradigms

A new study suggests a knowledge gap in Primary Care Providers' familiarity with screening guidelines could also be a barrier to successful implementation.